James Craig, MD
Family Medicine · Ellijay, GANPI 1811972987
Payments from drug & device makers
Across 87 payments — averaging $190.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$15K
- Braeburn Inc.$710
- AbbVie$283
- Indivior Inc.$143
- Johnson & Johnson$105
- Vanda Pharmaceuticals Inc.$79
- plus $297 from 9 others
What the payments were for
- Consulting fees$7404%
- Speaking & faculty fees$12,76077%
- Travel & lodging$1,2638%
- Food & beverage$1,75311%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 26 | $14,932 |
| Braeburn Inc. | 10 | $710 |
| AbbVie(2 entities) | 22 | $283 |
| Indivior Inc. | 6 | $143 |
| Johnson & Johnson | 4 | $105 |
| Vanda Pharmaceuticals Inc. | 4 | $79 |
| Orexo US, Inc. | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Titan Pharmaceuticals, Inc. | 1 | $25 |
| USWM, LLC | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,549 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $2,187 |
| Pregabalin | 21 | $1,211 |
| Naltrexone Hcl | 19 | $935 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $536 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $468 |
| Gabapentin | 17 | $228 |
| Quetiapine Fumarate | 26 | $176 |
| Mirtazapine | 12 | $147 |
| Oxycodone Hcl | 13 | $125 |
| Trazodone Hcl | 15 | $109 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Ellijay
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.